Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Padcev for urothelial cancer treatment
Enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck) have been given accelerated approval by the Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Share This Post

Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally advanced or metastatic urothelial carcinoma who can not get cisplatin-containing chemotherapy.

Efficacy was assessed in the multi-cohort (dose escalation cohort, Cohort A, Cohort K) research EV-103/KEYNOTE-869 (NCT03288545). Patients were treated with enfortumab vedotin-ejfv + pembrolizumab in the dose escalation cohort and Cohort A, whereas in Cohort K, patients were randomised to either the combination or enfortumab vedotin-ejfv alone. Patients were ineligible for chemotherapy that contained cisplatin because they had not previously undergone systemic treatment for locally progressed or metastatic illness. 121 individuals in total received pembrolizumab together with enfortumab vedotin-ejfv.

Objective response rate (ORR) and duration of response (DoR), which were determined by blinded independent central review using RECIST v1.1, were the key efficacy outcome measures. In 121 patients, the confirmed ORR was 68% (95% CI: 59, 76), with 12% of patients achieving full responses. The dosage escalation cohort and Cohort A had a median DoR of 22 months (interquartile range: 1+ to 46+), while Cohort K did not reach the median DoR (interquartile range: 1 to 24+).

Increased glucose, increased aspartate aminotransferase, rash, decreased haemoglobin, increased creatinine, peripheral neuropathy, decreased lymphocytes, fatigue, increased alanine aminotransferase, decreased sodium, increased lipase, decreased albumin, alopecia, decreased phosphate, decreased weight, diarrhoea, pruritus, decreased appetite, nausea, dysgeusia, decreased potassium, decreased sodium were the most frequent adverse reactions (>20%), along with

When combined with pembrolizumab, the recommended dose of enfortumab vedotin-ejfv is 1.25 mg/kg (up to 125 mg for patients under 100 kg), given intravenously over 30 minutes on Days 1 and 8 of a 21-day cycle until disease progression or intolerable toxicity. After receiving enfortumab vedotin on the same day, the dosage of pembrolizumab is advised to be 200 mg every three weeks or 400 mg every six weeks until the disease progresses, there is intolerable toxicity, or up to 24 months have passed.

View full prescribing information for Padcev and Keytruda. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy